Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Operating Expenses (2018 - 2025)

Historic Operating Expenses for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $132.6 million.

  • 10x Genomics' Operating Expenses fell 1754.29% to $132.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $504.9 million, marking a year-over-year decrease of 1710.48%. This contributed to the annual value of $504.9 million for FY2025, which is 1710.48% down from last year.
  • Per 10x Genomics' latest filing, its Operating Expenses stood at $132.6 million for Q4 2025, which was down 1754.29% from $132.5 million recorded in Q3 2025.
  • 10x Genomics' 5-year Operating Expenses high stood at $190.3 million for Q3 2023, and its period low was $95.0 million during Q2 2025.
  • Moreover, its 5-year median value for Operating Expenses was $143.6 million (2022), whereas its average is $141.1 million.
  • The largest annual percentage gain for 10x Genomics' Operating Expenses in the last 5 years was 6777.36% (2021), contrasted with its biggest fall of 7379.98% (2021).
  • 10x Genomics' Operating Expenses (Quarter) stood at $131.8 million in 2021, then grew by 8.15% to $142.5 million in 2022, then grew by 19.98% to $171.0 million in 2023, then dropped by 5.95% to $160.8 million in 2024, then fell by 17.54% to $132.6 million in 2025.
  • Its Operating Expenses was $132.6 million in Q4 2025, compared to $132.5 million in Q3 2025 and $95.0 million in Q2 2025.